An attempt to reign in the skyrocketing prices of some prescription drugs by requiring drug makers to inform the state of large drug price increases and the rationale for them is going to the governor.
Dubbed the “Prescription Drug Price Transparency Act,” the bill would require drug makers to report the reasons for price increases and provide other detailed information about the cost of manufacturing, marketing and distributing drugs, beginning Oct. 1, 2021. It would require price transparency for existing drugs, new drugs and newly acquired drugs.
The bill would apply to prescription drugs that cost $100 or more for a 30-day supply; brand name drugs with a price increase of 10% or more over the prior year or 16% in the prior two years, and generic drugs whose price increases 50% or more over the prior year.
Drug makers whose drugs meet those thresholds would have to report sales revenue for the drug in the past year; their net profit thanks to the drug; the amount of financial assistance they provided through patient prescription assistance programs; and any agreement between the drug maker and another entity to delay a generic version and other information.
Those large drug price increases would be posted on the Department of Health website. Drug makers that failed to follow the law would be subject to fines of up to $10,000 per day, and other civil penalties.
Every January, the Health Department would report to the Legislature a summary of the drug price increases.
Morrison said the proposal brings much-needed transparency to prescription drug pricing.
“The cost of prescription drugs is high and growing higher, including older drugs and new drugs entering the market,” she said. “While drug manufacturers create life-changing and life-sustaining medication, these medications are useless if people can’t afford them.”
Currently, 23 cents of every dollar spent on health care goes to prescription drugs, more than in-patient hospital costs, she said. Among the “egregious” price increases she cited:
“These are life-saving or sustaining drugs,” Morrison said. “Patients can’t choose whether or not they want to buy these drugs; they can’t shop around for a better deal. They need them to live.”
Rep. Glenn Gruenhagen (R-Glencoe), who originally was a bill co-sponsor, said he removed his name after talking to a local pharmacist and deciding it might hurt patients and their access. He said federal legislation will address drug prices.
Morrison said similar language was included in a 2019 omnibus bill, but disagreements over trade secrets derailed its enactment. However, lawmakers have since worked with the pharmaceutical and generics industry to strengthen trade secret protection, she said, noting the bill is also supported by a broad coalition of stakeholders, including the business community, patient and provider groups, unions and health plans.